Global perspectives of emerging occupational and environmental lung diseases

Moitra, Subhabrata; Puri, Rajan; Paul, Devon W.; Huang, Yuh‐Chin T.

doi:10.1097/mcp.0000000000000136

Cited by 43 publications

(29 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After initial screening, thirty studies were excluded either because of duplicate citations ( n = 24) or not related to PAP ( n = 6). [363738394041] Remaining 39 studies were selected for further analysis. Among these, 5 studies were not from India,[4243444546] seven studies were review articles,[47] meta-analysis,[48] laboratory experiments,[4950] comments,[51] replies to previous comments,[52] or quiz[53] and they were excluded from the study.…”

Section: Resultsmentioning

confidence: 99%

Pulmonary alveolar proteinosis: Experience from a tertiary care center and systematic review of Indian literature

et al. 2016

View full text Add to dashboard Cite

Background:Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by deposition of lipoproteinaceous material within alveoli, with a variable clinical course. Here, we report an experience of management of PAP at our center. A systematic review of previously reported cases from India is also included in the article.Materials and Methods:This study included patients with primary PAP managed at our center from 2009 to 2015. Diagnosis of primary PAP was based on histopathologic diagnosis on bronchoalveolar lavage or transbronchial lung biopsy and absence of causes of secondary PAP. For systematic review of Indian publications, the literature search was performed using PubMed and EMBASE databases using the terms “pulmonary alveolar proteinosis'” or “alveolar proteinosis” and “India” or “Indian.”Results:During the above-specified period, five patients with diagnosis of PAP were admitted at our center. Median age of patients was 32 years (interquartile range [IQR] 30.5–59); 80% were female. Mean duration (± standard deviation) of symptoms was 6.2 (±1.79) months. Anti-granulocyte-macrophage colony stimulating factor (GM-CSF) antibodies were elevated in 4 out of 5 patients (80%). For management, whole lung lavage (WLL) was done for four patients with median volume of 32.5 (IQR 18–74) L per patient. All the patients showed significant symptomatic as well as improvement in physiological parameters. Subcutaneous GM-CSF and ambroxol were given to 3 patients and 1 patient, respectively. The median follow-up of all patients was 18 (IQR 5–44) months. A systematic review of all Indian studies of PAP revealed thirty publications.Conclusions:WLL is the most common, effective, and safe therapy in patients with PAP. GM-CSF administration is an efficacious treatment for patients with incomplete response after WLL.

show abstract

Section: Resultsmentioning

confidence: 99%

Pulmonary alveolar proteinosis: Experience from a tertiary care center and systematic review of Indian literature

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Iako je pušenje cigareta najbolje proučen faktor rizika , i aerozagađenje, zadnjih godina postoje i studije koje dokazuju da i nepušači mogu da razviju opstrukciju sa ograničenjem protoka vazduha.Genetski faktori, kao što je deficit alfa -1 -antitripsina, zatim gen koji kodira matriksnu metiloproteinazu (MMP12), dovode se u vezu sa opadanjem plućne funkcije [3,5,6 ]. Inflamacija u plućima kod obolelih od HOBP-a je najverovatnije reakcija respiratornog trakta na hronične iritanse poput duvanskog dima.Oksidativni stres i višak proteinaza takođe modifikuju inflamaciju u plućima.Specifični obrazac inflamacije se karakteriše i povećanjem broja CD8+ (citotoksičnih )limfocita.Veliki broj medijatora zapaljenja privlači inflamatorne ćelije i iz cirkulacije, čime se pojačava zapaljenski proces i indukuju strukturne promene.Broj inflamatornih ćelija se povećava i u perifernoj krvi.…”

Section: Uvodunclassified

The most frequent comorbidities at patients with the chronic obstructive pulmonary disease

Krdzic¹,

Milovanović²,

Šipić³

et al. 2018

Praxis medica

View full text Add to dashboard Cite

Hronična opstruktivna bolest pluća (HOBP) je bolest sa periodima remisije i egzacerbacije i posledičnim oštećenjem plućne funkcije. Procena je da godišnje umire oko tri miliona ljudi , a predviđa se da do 2030 godine broj umrlih ide i do 6 miliona na godišnjem nivou. Prema izveštajima Svetske zdravstvene organizacije i Globalne inicijative za hronične opstruktivne bolesti pluća (GOLD) predviđa se i da će u sledećoj deceniji HOBP biti treća bolest u svetu po smrtnosti [ 1, 2 ]. Karakteriše se ograničenim protokom vazduha u disajnim putevima koje nije u potpunosti reverzibilno na terapiju. Sobzirom da se u HOPB-u dešava i sistemska inflamacija, mehanizmi ovih dešavanja imaju posledice i van pluća. Komorbiditeti su česti u oboleih od hronične opstrukcijske bolesti pluća i znatno utiču na prognozu bolesti. Najčešći komorbiditeti su kardiovaskularne bolesti, metabolički sindrom, dijabetes, anemija, osteoporoza, anksioznost i depresija, plućna embolija.

show abstract

“…In miners in South Africa, India, and China, silicosis has been shown to have a multiplicative effect, together with HIV, as a risk factor for pulmonary TB. 86,87 In the pre-ART era, LIP was the leading cause of CLD in children, prevalent in 30 to 40% of HIV-infected children in both highincome and LMIC settings. LIP responds well to ART and its incidence has declined significantly with the availability of ART.…”

Section: Chronic Respiratory Diseasementioning

confidence: 99%

Global Considerations in Human Immunodeficiency Virus-Associated Respiratory Disease

Rylance

Meghji

Miller

et al. 2016

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Respiratory tract infection, particularly tuberculosis, is a major cause of mortality among human immunodeficiency virus (HIV)-infected individuals. Antiretroviral therapy (ART) has resulted in a dramatic increase in survival, although coverage of HIV treatment remains low in many parts of the world. There is a concurrent growing burden of chronic noninfectious respiratory disease as a result of increased survival. Many risk factors associated with the development of respiratory disease, such as cigarette smoking and intravenous drug use, are overrepresented among people living with HIV. In addition, there is emerging evidence that HIV infection may directly cause or accelerate the course of chronic lung disease. This review summarizes the clinical spectrum and epidemiology of respiratory tract infections and noninfectious pulmonary pathologies, and factors that explain the global variation in HIV-associated respiratory disease. The potential for enhancing diagnoses of noninfective chronic conditions through the use of clinical algorithms is discussed. We also consider issues in assessment and management of HIV-related respiratory disease in view of the increasing global scale up of ART.

show abstract

Global perspectives of emerging occupational and environmental lung diseases

Cited by 43 publications

References 66 publications

Pulmonary alveolar proteinosis: Experience from a tertiary care center and systematic review of Indian literature

Pulmonary alveolar proteinosis: Experience from a tertiary care center and systematic review of Indian literature

The most frequent comorbidities at patients with the chronic obstructive pulmonary disease

Global Considerations in Human Immunodeficiency Virus-Associated Respiratory Disease

Contact Info

Product

Resources

About